ONYX-015, an E1b gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

Nature Medicine

Volumn 3, Issue 6, 1997, Pages 639-645

  Heise, Carla ^a   Sampson Johannes, Adam ^a   Williams, Angelica ^a   McCormick, Frank ^c   Von Hoff, Daniel D ^b   Kirn, David H ^a  

^a ONYX PHARMACEUTICALS   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; PROTEIN P53;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TRANSGENE; TUMOR SUPPRESSOR GENE; VIRUS REPLICATION; XENOGRAFT;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ANTIGENS, VIRAL; CAPSID; CAPSID PROTEINS; CELLS, CULTURED; CHEMOTHERAPY, ADJUVANT; CISPLATIN; ENDOTHELIUM, VASCULAR; EPITHELIUM; FEMALE; FLUOROURACIL; GLIOBLASTOMA; HUMANS; INJECTIONS, INTRALESIONAL; LARYNGEAL NEOPLASMS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 0030917202     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0697-639     Document Type: Article

References (15)

1. Lowe, S.W., Ruley, H.E., Jacks, T. & Housman, D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967 (1993).
2. Fujiwara, T. et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 54, 2287-2291 (1994).
3. Lowe, S.W. et al. p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810 (1994).
4. Fearon, E.R., Hamilton, S.R. & Vogelstein, B. Clonal analysis of human colorectal tumors. Science 238, 193-197 (1987).
5. Brennan, J.A. et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 332, 429-435 (1995).
6. Chang, F., Syrjanen, S. & Syrjanen, K. Implications of the p53 tumor-suppressor gene in clinical oncology. J. Clin. Oncol. 13, 1009-1022 (1995).
7. Bergh, J., Norberg, T., Sjögren, S., Lindgren, A. & Holmberg, L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med. 1, 1029-1034 (1995).
8. Eliopoulos, A.G. et al. The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2. Oncogens 11, 1217-1228 (1995).
9. Debbas, M. & White, E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by El B. Genes Dev. 7, 546-554 (1993).
10. Grand, R.J., Grant, M.L. & Gallimore, P.H. Enhanced expression of p53 in human cells infected with mutant adenoviruses. Virology 203, 229-240 (1994).
11. Lowe, S.W., Ruley, H.E., Jacks, T. & Housman, D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967 (1993).
12. Lechner, M.S. et al. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J. 11, 3045-3052 (1992).
13. Gannon, J.V. & Lane, D.P. p53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature 329, 456-458 (1987).
14. Barker, D.D. & Berk, A.J. Adenovirus proteins from both El B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156, 107-121 (1987).
15. Slichenmeyer, W.J., Nelson, W.G., Slebos, R.J. & Kastan, M.B. Loss of a p53-associated G1 checkpoint does not decrease cell survival Cancer Res. 53, 4164-4169 (1993).